Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor TherapyJames N. Ingle, Liewei Wang, Fang Xie et al.|Cancer Research|2016Cited by 78
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trialPaul E. Goss, Lois E. Shepherd, Dawn L. Hershman et al.|The Lancet Oncology|2014Cited by 53
Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor TrialVered Stearns, Paul E. Goss, Judith‐Anne W. Chapman et al.|Journal of Clinical Oncology|2014Cited by 43
TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response.SJ Isakoff, Leif W. Ellisen, Paul E. Goss et al.|Journal of Clinical Oncology|2011Cited by 35
Supplementary Figure S3 from Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor TherapyJames N. Ingle, Liewei Wang, Poulami Barman et al.|Unknown|2023Cited by 0